RNA-based therapeutics: current progress and future prospects - PubMed (original) (raw)

Review

RNA-based therapeutics: current progress and future prospects

John C Burnett et al. Chem Biol. 2012.

Abstract

Recent advances of biological drugs have broadened the scope of therapeutic targets for a variety of human diseases. This holds true for dozens of RNA-based therapeutics currently under clinical investigation for diseases ranging from genetic disorders to HIV infection to various cancers. These emerging drugs, which include therapeutic ribozymes, aptamers, and small interfering RNAs (siRNAs), demonstrate the unprecedented versatility of RNA. However, RNA is inherently unstable, potentially immunogenic, and typically requires a delivery vehicle for efficient transport to the targeted cells. These issues have hindered the clinical progress of some RNA-based drugs and have contributed to mixed results in clinical testing. Nevertheless, promising results from recent clinical trials suggest that these barriers may be overcome with improved synthetic delivery carriers and chemical modifications of the RNA therapeutics. This review focuses on the clinical results of siRNA, RNA aptamer, and ribozyme therapeutics and the prospects for future successes.

Copyright © 2012 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Common chemical modifications of therapeutic nucleic acid analogs. The unmodified RNA structure is shown next to backbone (5’-phosphorothioate), LNA, and 2’-substitutions (2’-O-methoxy-ethyl, 2’-O-methyl, and 2’-fluoro).

Figure 2

Figure 2

Mammalian PTGS pathway for miRNAs, shRNAs, and siRNAs (A) miRNAs are transcribed from DNA as primary miRNAs (pri-miRNAs) and processed into 70-nt stem-loop precursor miRNAs (pre-miRNAs) by Drosha and DGCR8. The pre-miRNAs are transported to the cytoplasm by dsRNA-binding protein exportin 5, where they are processed into ~22 nt miRNA duplexes by the Dicer/TRBP complex. The imperfectly complementary miRNA duplexes associate with an AGO protein and are loaded into RISC, where the passenger strand is removed and the guide strand remains to target mRNA for silencing. The resulting mature RISC complex may silence gene expression either by inhibiting the initiation of translation or by transporting the complex to cytoplasmic processing bodies (p-bodies) where the mRNA is deadenylated and destroyed. (B) Like miRNAs, shRNAs are transcribed from DNA and undergo similar processing. However, the perfect Watson-Crick base-pairing between the guide strand and the target mRNA triggers AGO2-mediated cleavage of the mRNA target. (C) In contrast to shRNAs, siRNAs are artificially introduced into the cytoplasm. All steps of siRNA and shRNA are the same after processing by Dicer/TRBP.

Similar articles

Cited by

References

    1. Guerrier-Takada C, Gardiner K, Marsh T, Pace N, Altman S. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell. 1983;35:849–857. - PubMed
    1. Kruger K, Grabowski PJ, Zaug AJ, Sands J, Gottschling DE, Cech TR. Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell. 1982;31:147–157. - PubMed
    1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806–811. - PubMed
    1. Melnikova I. RNA-based therapies. Nature Reviews Drug Discovery. 2007;6:863–864. - PubMed
    1. Peer D, Lieberman J. Special delivery: targeted therapy with small RNAs. Gene Ther. 2011 - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources